RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $90.00.

The shine is where this tinted lip oil truly steals the show. Described as “the perfect color,” one fan of the Berry Involved ...

The sixth and final season of the award-winning Hulu drama will be a “love letter” to fans who’ve stuck with it through five grueling seasons of often agonizing events, showrunner Yahlin Chang ...

The speaker of the Ekiti State House of Assembly, Adeoye Aribasoye, has called on political and legislative institutions in the country to create more opportunities for women.While lamenting the low ...

Alphabet's new Willow processor exponentially reduces quantum computing errors. Microsoft says its breakthrough processor means the practical uses for quantum computing are no longer decades away ...

The Speaker, Ekiti State House of Assembly, Adeoye Aribasoye, has decried the low participation of women in politics, stressing the need for proactive measures to address their under-representation in ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $117.39. The firm’s 50 day moving average is $99.15 and its 200-day moving average is $91.09.

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need.